Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168636 | 0.85 | KMT2A (0.41) | ALDH1A1KMT2ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL16523504 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL16523503 | 0.80 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL16523502 | 0.79 | ALDH1A1 (0.45) | ALDH1A1LMNAKMT2ASMN1; SMN2HPGD | |
| SCHEMBL6508886 | 0.79 | ALDH1A1 (0.45) | ALDH1A1LMNAHPGDTSHRCYP1A2 | |
| SCHEMBL3936080 | 0.78 | RAB9A (0.62) | ALDH1A1LMNAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13638790 | 0.77 | NPC1 (0.47) | ALDH1A1LMNAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL205849 | 0.77 | MEN1 (0.40) | ALDH1A1KMT2ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL78064 | 0.77 | ALDH1A1 (0.47) | ALDH1A1LMNAHPGDTSHRMAPT | |
| SCHEMBL16515501 | 0.77 | ALDH1A1 (0.44) | ALDH1A1LMNAKMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| EP-3036237-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | Fujian Haixi Pharmaceuticals Co. Ltd (CN) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015024526-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015024526-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2015-02-26 | — | — | WO | disclosed |
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2248812-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | GPR119, GLP1R, INSR | ALDH1A1 459/4885LMNA 3627/4885KMT2A 4186/4885 |
| US-20140080891-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | ALDH1A1 3122/4885LMNA 4399/4885KMT2A 3963/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | ALDH1A1 3122/4885LMNA 4399/4885KMT2A 3963/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | ALDH1A1 3122/4885LMNA 4399/4885KMT2A 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.